SAN DIEGO, March 9, 2020 /PRNewswire/ -- Biocept,
Inc. (Nasdaq: BIOC), a leading commercial provider of liquid
biopsy tests designed to provide physicians with clinically
actionable information to improve the outcomes of patients
diagnosed with cancer, announces the publication of clinical data
in the peer-reviewed Journal of Clinical Pathology that
further validates the Company's Target Selector™ qPCR Assay using
"Switch Blocker" technology to identify cancer-related mutations in
liquid biopsy samples. The article can be found at
https://jcp.bmj.com/content/early/2020/03/04/jclinpath-2019-206381.
"Results from this study showed a very high concordance rate
between our liquid biopsy testing and tissue biopsy, providing
further clinical validation of our Target Selector™ technology,"
said Veena Singh, M.D., Biocept's Senior Vice President and
Senior Medical Director. "Our clinical testing demonstrates
best-in-class detection of alterations down to a single mutant
copy, not only in an analytical setting but in a clinical setting
as well. Further the ability to inform clinical decision making in
a significantly more cost-effective manner potentially affords the
healthcare system a highly sensitive and cost-effective
option."
The study examined 127 clinical assays for mutations commonly
associated with cancer found in the EGFR, BRAF and KRAS genes. Each
Target Selector™ assay in the study demonstrated extremely high
accuracy, sensitivity and specificity when compared to results
obtained from tissue samples, showing a 93%-96% concordance to
blinded tissue samples across all assays.
"The continued validation of our technology demonstrates its
ability to non-invasively identify biomarkers specific to cancer,
and to aid physicians in selecting optimal therapeutic treatments
for their patients," said Michael
Nall, Biocept's President and Chief Executive
Officer. "We are pleased to report that our biomarker testing
has been performed in more than 25,000 patients to date, and
results from this study further illustrate the enhanced performance
of our Target Selector™ technology."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the platform has
demonstrated the ability to identify cancer mutations and
alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please visit
www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to inform clinical
decision making in a significantly more cost-effective
manner, our ability to improve the outcomes of patients
diagnosed with cancer, and the potential clinical utility of
our proprietary technology platform, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
Media:
CORE IR
Jules Abraham
julesa@coreir.com
917-885-7378
View original content to download
multimedia:http://www.prnewswire.com/news-releases/newly-published-data-in-journal-of-clinical-pathology-provides-clinical-validation-for-biocepts-target-selector-qpcr-assay-to-identify-cancer-associated-mutations-301019347.html
SOURCE Biocept, Inc.